Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (478)	7/14/2004 9:24:51 AM
From: nigel bates	Read Replies (1) \| Respond to of 933

Hsp90 Neutec are seeking a partner to trial 'Mycograb' in cancer - could it get used off label if it gets approved (as seems likely) next year ? Message 20301390

To: scaram(o)uche who wrote (478)	8/31/2004 12:49:35 PM
From: tuck	Read Replies (1) \| Respond to of 933

On Thursday, 9/30, N. Zaffaroni will be presenting a paper at the EORTC meeting concerning how the silencing of of the survivin gene by siRNA induces apoptosis in prostate cancer cells and sensitizes them to 17-AAG. I can only find the title. If abstracts are publicly available, I can't find 'em. FWIW, Isis and Lilly have an antisense molecule heading for the clinic that targets the survivin gene; it is the only commercial project I know of that does so (various molecules down regulate it, but none specifically targets it). Cheers, Tuck